Related Research Articles
James Lewis Abbruzzese is the Chief of the Duke Division of Medical Oncology and associate director for Clinical Research for the Duke Cancer Institute. Previously,Abbruzzese was Chairman of the Department of Gastrointestinal Medical Oncology at the University of Texas M. D. Anderson Cancer Center where he held the M. G. and Lillie A. Johnson Chair for Cancer Treatment and Research and the Annie Laurie Howard Research Distinguished Professorship. Abbruzzese is one of the world's leaders in the clinical study and treatment of pancreatic cancer.
Todd R. Golub is a professor of pediatrics at the Harvard Medical School,the Charles A. Dana Investigator in Human Cancer Genetics at the Dana–Farber Cancer Institute,and the Director and a founding member of the Broad Institute of MIT and Harvard. He is a world leader in applying genomic tools to cancer research,having made important discoveries in the molecular basis of childhood leukemia.
Alan D. D'Andrea is an American cancer researcher and the Fuller American Cancer Society Professor of Radiation Oncology at Harvard Medical School. D'Andrea's research at the Dana Farber Cancer Institute focuses on chromosome instability and cancer susceptibility. He is currently the director of the Center for DNA Damage and Repair and the director of the Susan F. Smith Center for Women's Cancer.
Kenneth Offit is an American cancer geneticist and oncologist. He is currently Chief of the Clinical Genetics Service and the Robert and Kate Niehaus Chair in Inherited Cancer Genomics at Memorial Sloan Kettering Cancer Center. Offit is also a member of the Program in Cancer Biology and Genetics at the Sloan-Kettering Institute,Professor of Medicine and Healthcare Policy and Research at Weill Cornell Medical College,and a member of both the Board of Scientific Counselors of the National Cancer Institute and the Evaluation of Genomic Applications in Practice and Prevention working group of the U.S. Centers for Disease Control.
Eric P. Winer is a medical oncologist and clinical researcher specializing in breast cancer. He is director of Yale Cancer Center and physician-in-chief of Smilow Cancer Hospital at Yale New Haven Health,effective February 1,2022. He also is Deputy Dean for Cancer Programs at the Yale School of Medicine. From 1997 to 2021,he was the Chief of the Breast Oncology Program at Dana–Farber Cancer Institute in Boston,Massachusetts. Beginning in 2013,he held a range of institutional roles at Dana-Farber,including Chief of Clinical Development,the Thompson Chair in Breast Cancer Research and Director of the Dana-Farber/Harvard SPORE in Breast Cancer. He also served as a Professor of Medicine at Harvard Medical School. He was president of the American Society of Clinical Oncology (ASCO) 2022-2023 and became Chair of the Board in mid-June 2023. His career has been focused on breast cancer treatment and research.
Lynda Chin is a Chinese-American medical doctor. She is a board-certified dermatologist who was the founding department chair and professor of genomic medicine at the University of Texas MD Anderson Cancer Center,as well as scientific director of the MD Anderson Institute for Applied Cancer Science. In late 2012 she was elected as a member of the Institute of Medicine (IOM) of the National Academies.
William G. Kaelin Jr. is an American Nobel laureate physician-scientist. He is a professor of medicine at Harvard University and the Dana–Farber Cancer Institute. His laboratory studies tumor suppressor proteins. In 2016,Kaelin received the Albert Lasker Award for Basic Medical Research and the AACR Princess Takamatsu Award. He also won the Nobel Prize in Physiology or Medicine in 2019 along with Peter J. Ratcliffe and Gregg L. Semenza.
David M. Livingston was the Deputy Director of the Dana-Farber/Harvard Cancer Center,Emil Frei Professor of Genetics and Medicine at Harvard Medical School,Chairman of the Executive Committee for Research at Dana–Farber Cancer Institute. Dr. Livingston joined the Harvard faculty in 1973. His research focused on breast and ovarian cancer.
Mary-Ellen Taplin,is a research oncologist at Dana Farber Cancer Institute and Brigham and Women's Hospital in Harvard's Longwood Medical and Academic Area.
Charis Eng is a Singapore-born physician-scientist and geneticist at the Cleveland Clinic,notable for identifying the PTEN gene. She is the Chairwoman and founding Director of the Genomic Medicine Institute of the Cleveland Clinic,founding Director and attending clinical cancer geneticist of the institute’s clinical component,the Center for Personalized Genetic Healthcare,and Professor and Vice Chairwoman of the Department of Genetics and Genome Sciences at Case Western Reserve University School of Medicine.
Ann Hart Partridge is an American medical oncologist. She is the founder and director of the Young and Strong Program for Young Women with Breast Cancer at the Susan F. Smith Center for Women's Cancers at the Dana–Farber Cancer Institute.
Catherine J. Wu is an American physician-scientist who studies oncology. She is a Professor of Medicine and Chief of Division of Stem Cell Transplantation and Cellular Therapies at the Dana–Farber Cancer Institute. Her research focuses on longitudinal studies of patients with chronic lymphocytic leukemia (CLL).
Scott Allen Armstrong is an American pediatric oncologist and cancer biologist focused on chromatin-based control of gene expression in cancer and therapeutic discovery. Armstrong and his team were the first to isolate rare leukemia stem cells in a mouse model of leukemia.
Margaret Ann Shipp is an American hematologic oncologist. She is the Douglas S. Miller Chair in Hodgkin Lymphoma at Harvard Medical School. Shipp is an elected Fellow of the American Society for Clinical Investigation and National Academy of Medicine.
Monica Bertagnolli is an American surgical oncologist and the 16th director of the National Cancer Institute. Previously,she worked at Brigham and Women's Hospital and Dana–Farber Cancer Institute and was the Richard E. Wilson Professor of Surgery at Harvard Medical School. She has advocated for inclusion of rural communities in clinical studies and served as Chair of the Alliance for Clinical Trials in Oncology until her appointment to lead NCI. Bertagnolli specializes in the treatment of tumors from gastrointestinal diseases and soft tissue sarcomas. She is the former President of the American Society of Clinical Oncology and was elected Fellow of the National Academy of Medicine in 2021. In 2023,President Biden nominated Bertagnolli to serve as the director of the National Institutes of Health. If confirmed,she would be the second woman director of the NIH.
Matthew Langer Meyerson is an American pathologist and the Charles A. Dana Chair in Human Cancer Genetics at the Dana-Farber Cancer Institute. He is also director of the Center for Cancer Genomics at the Dana-Farber Cancer Institute,and the Director of Cancer Genomics at the Broad Institute of MIT and Harvard.
Benjamin Levine Ebert is the Chair of Medical Oncology at the Dana–Farber Cancer Institute and the George P. Canellos,MD and Jean S. Canellos Professor of Medicine at Harvard Medical School.
Nancy Lin is an American oncologist who works at the Dana-Farber Cancer Institute and is an Associate Professor of Medicine at Harvard Medical School. Her research considers new diagnostic strategies and treatment pathways for HER2 positive breast cancer.
William Pao is an oncologist and Executive Vice President and Chief Development Officer of Pfizer. He was previously the head of Pharma Research and Early Development (pRED) at Roche and a professor of medicine at the Vanderbilt University Medical Center. He is best known for his work in molecular oncology and cancer genomics.
James D. Griffin is an American physician-scientist. He is currently Professor of Medicine at Harvard Medical School,Chair of Medical Oncology at Dana–Farber Cancer Institute,and Director of Medical Oncology at Brigham and Women's Hospital. He is considered an expert in medical oncology and is widely recognized for his research in the clinical and biologic aspects of hemotologic malignancies.
References
- ↑ "Dr. Levi Garraway CV". roche.com. Retrieved May 28, 2023.
- 1 2 3 Garraway, Levi A. (December 1, 2016). "Believe the miracles: of biomedical science and human suffering". Journal of Clinical Investigation . 126 (12): 4716–4722. doi:10.1172/JCI90893. PMC 5127662 . PMID 27906693.
- ↑ "Special Spotlight: Levi A. Garraway, M.D., Ph.D., Receives Prestigious Jane Cooke Wright Award from American Association for Cancer Research". cancer.gov. April 17, 2014. Retrieved May 28, 2021.
- ↑ "Garraway details family's key role in shaping career path". news.vumc.org. October 12, 2017. Retrieved May 28, 2021.
- 1 2 3 Rimas, Andrew (September 24, 2007). "He trolls genome for cancer clues". The Boston Globe. Retrieved May 28, 2021– via newspapers.com.
- ↑ "LEVI GARRAWAY". broadinstitute.org. Broad Institute . Retrieved May 28, 2021.
- 1 2 "Levi Garraway: A passion for purpose". roche.com. Roche Holding AG. October 8, 2019. Retrieved May 28, 2021.
- 1 2 "Levi Garraway, MD, PhD". the-asci.org. American Society for Clinical Investigation . Retrieved May 28, 2021.
- ↑ Burke, Afrienne (February 21, 2012). "Foundation Medicine: Personalizing Cancer Drugs". MIT Technology Review. Retrieved May 28, 2021.
- ↑ Meade-Kelly, Veronice (September 26, 2013). "Levi Garraway awarded Paul Marks Prize for Cancer Research". broadinstitute.org. Retrieved May 28, 2021.
- ↑ "Researcher receives achievement award". healio.com. December 1, 2012. Retrieved May 28, 2021.
- ↑ "Levi Garraway, M.D., Ph.D., to become Senior Vice President of Global Oncology at Lilly, Succeeding Richard Gaynor, M.D., Who is Retiring after a Distinguished Career". investor.lilly.com. September 14, 2016. Retrieved May 28, 2021.
- ↑ "LEVI A. GARRAWAY, MD, PHD". aacr.org. Retrieved May 28, 2021.
- ↑ "National Academy of Medicine elects 100 new members". eurekalert.org. Eurekalert. October 19, 2020. Retrieved May 28, 2021.
- ↑ Curlee, Elizabeth (June 14, 2007). "A Deeper Reason For Cancer Research". cbsnews.com. CBS News. Retrieved May 28, 2021.